Coulter Partners successfully completed a search assignment for ARTIDIS and is pleased to announce the placement of Dominique Leutwyler as Chief Financial Officer (CFO).

Dominique Leutwyler is a highly experienced finance leader with a strong track record in the Swiss MedTech industry. He played a key role in the successful growth of Medartis, a medical device company, from a startup to a global leader. His experience includes international expansion, acquisitions, and a successful IPO.

Commenting on the collaboration with Coulter Partners, Dr Marija Plodinec, Ph.D., Co-founder and CEO of ARTIDIS, said:

“Coulter Partners showcased a profound understanding of our industry and our company’s unique needs. Their expertise and extensive network enabled them to deliver exceptional candidates. We're very happy with the outcome as we welcome Dominique to our team.”

ARTIDIS AG is a Swiss health technology company on a mission to revolutionize cancer care by moving diagnostic and treatment response analyses from central laboratories to the patient's bedside. They have developed the first nanomechanical biomarker for cancer, enabling faster and more precise diagnoses and treatment predictions immediately after a biopsy is taken.

----

Dominique Leutwyler, Chief Financial Officer at ARTIDIS

Dominique brings over 25 years of leadership experience in financial strategy and organizational growth, with a remarkable track record in the Swiss MedTech industry. Most notably, Dominique served as CFO at Medartis, where he helped transform the company from a small startup into a global leader in trauma medical devices. Under his leadership, Medartis achieved significant milestones, including international expansion, strategic acquisitions, and a successful IPO on the SIX Swiss Exchange in 2018.

About ARTIDIS

ARTIDIS AG is on a mission to shift the paradigm of cancer care from central lab to patient bedside by providing fast and precise diagnosis and prediction of treatment response immediately after the biopsy is taken. The clinical stage health technology company located in Basel, Switzerland, has developed the first nanomechanical biomarker for cancer diagnosis and treatment optimization. Through generating these unique insights ARTIDIS is positioning its technology as a standard of care for tissue analysis and therapy optimization, thereby bringing benefits to both the patient and the healthcare system.

For more information, please visit www.artidis.com

About Coulter Partners

We are executive search and leadership development specialists working to build a better future. As advisors and consultants to companies at the cutting edge of Health, Science, and Technology, we are united by our mission to build teams that change the world. Operating uniquely as one global team, we have honed our expertise, platform, and data for over two decades, working across three continents, and in 40 countries. Applying what we learn through our work with boards, leadership teams, and investors in the world’s most innovative companies, we bring together and develop the right people at the right time to propel them to achieve their worthwhile goals.

www.coulterpartners.com

Coulter Partners secures top finance Executive for ARTIDIS AG

About ARTIDIS

About Coulter Partners

Related

Evolution Italy: Life Science leaders gather for insightful discussions

Coulter Partners at BioCapital Europe 2025: Innovation and optimism reign

#Twenty25 - Funding the future of health tech - Part 19/20 Interview with Inga Deakin, Molten Ventures

BIA Gala Dinner 2025